Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation Nivolumab-Ipilimumab Versus Observation in Treatment-naive PD-L1+ Stage IV NSCLC (DICIPLE)
NCT03469960Phase 3Completed
- Sponsor
- IFCT
- Start
- May 2018
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in non-small cell lung cancer (NSCLC), sponsored by IFCT. Started May 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03469960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03469960.